Related Experiment Video
Updated: Feb 10, 2026

Autofluorescence Imaging to Evaluate Cellular Metabolism
Published on: November 15, 2021
Meaningful use and clinical utility of preemptive pharmacogenetic testing: (re)view from a CYP2D6 poor metabolizer
1Marion Merrell Dow/Missouri Endowed Chair in Pediatric Clinical Pharmacology, Director, Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Kansas City, Professor of Pediatrics and Pharmacology, Schools of Medicine and Pharmacy, University of Missouri-Kansas City, Missouri, USA.
Abstract:
The value of pharmacogenetic information at an individual level seems self-evident; demonstrating the value to the individual across a population appears to be much more difficult to demonstrate. Future studies should avoid single gene-drug pairs and a limited number of population-specific alleles that are insufficient to capture all relevant genetic variation within diverse populations, such as CYP2C9*2 and *3. Robust associations between cytochrome P450 (CYP) genotypes and treatment response require knowledge of drug exposure.
Related Concept Videos
Mitral Stenosis II: Clinical features and Diagnostic Tests
Mitral Regurgitation II: Clinical Features and Diagnostic Tests
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Pericarditis II: Clinical Features and Diagnostic Tests
Myocarditis II: Clinical Features and Diagnostic Tests
Aortic Regurgitation II: Clinical Features and Diagnostic Tests

